{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:46:09Z","timestamp":1784673969651,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["ACE052\/22\/000038"],"award-info":[{"award-number":["ACE052\/22\/000038"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["ACE052\/22\/000038"],"award-info":[{"award-number":["ACE052\/22\/000038"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["ACE052\/22\/000038"],"award-info":[{"award-number":["ACE052\/22\/000038"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["ACE052\/22\/000038"],"award-info":[{"award-number":["ACE052\/22\/000038"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["ACE052\/22\/000038"],"award-info":[{"award-number":["ACE052\/22\/000038"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001872","name":"Centro para el Desarrollo Tecnol\u00f3gico Industrial","doi-asserted-by":"publisher","award":["SNEO-20231326"],"award-info":[{"award-number":["SNEO-20231326"]}],"id":[{"id":"10.13039\/501100001872","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001872","name":"Centro para el Desarrollo Tecnol\u00f3gico Industrial","doi-asserted-by":"publisher","award":["SNEO-20231326"],"award-info":[{"award-number":["SNEO-20231326"]}],"id":[{"id":"10.13039\/501100001872","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001872","name":"Centro para el Desarrollo Tecnol\u00f3gico Industrial","doi-asserted-by":"publisher","award":["SNEO-20231326"],"award-info":[{"award-number":["SNEO-20231326"]}],"id":[{"id":"10.13039\/501100001872","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001872","name":"Centro para el Desarrollo Tecnol\u00f3gico Industrial","doi-asserted-by":"publisher","award":["SNEO-20231326"],"award-info":[{"award-number":["SNEO-20231326"]}],"id":[{"id":"10.13039\/501100001872","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001872","name":"Centro para el Desarrollo Tecnol\u00f3gico Industrial","doi-asserted-by":"publisher","award":["SNEO-20231326"],"award-info":[{"award-number":["SNEO-20231326"]}],"id":[{"id":"10.13039\/501100001872","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J NeuroEngineering Rehabil"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Late-onset Pompe disease (LOPD) presents with progressive muscle weakness, often leading to functional impairment that is challenging to monitor with conventional assessments. This study aims to develop and validate novel gait-based outcome measures for monitoring disease progression in individuals with LOPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Longitudinal study with genetically confirmed LOPD patients and age-and gait velocity-matched healthy controls that were assessed over a two-year period using the Ephion Mobility system, which integrates inertial sensors, plantar pressure insoles, and surface electromyography. All participants completed a free walking test (10\u201315\u00a0m at self-selected pace) and the 6-minute walk test (6MWT). Differences in gait features were identified using a three-stage feature selection framework that includes linear mixed-effects model, ElasticNet-regularized and bootstrap analysis. To explore intra-group variability within the LOPD cohort, we performed a clustering analysis. Based on the selected features and their weighted temporal changes, we developed a Pompe Mobility-Derived Progression Index (Pompe-MDPI) by training a Linear Discriminant Analysis (LDA) to discriminate between control and LOPD data. We calculated the Minimum Clinically Important Difference and compared its performance against the 6MWT distance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      24 LOPD and 39 healthy controls were included in the study. 46 gait features were found to significantly differentiate individuals with LOPD from controls (Holm-corrected\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), comprising 16 from trunk and pelvis joints, 18 from lower limb joints, 4 from force profiles, and 8 from EMG.Hierarchical clustering analysis revealed two distinct subgroups within the LOPD cohort, based on nine gait features. The computed Pompe-MDPI successfully discriminated between LOPD and healthy controls (AUC\u2009=\u20090.95), outperforming the 6MWT distance (AUC\u2009=\u20090.84). The Pompe-MDPI was also strongly associated with the 6MWT (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and demonstrated significant change over time in the LOPD group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The Pompe Mobility-Derived Progression Index (Pompe-MDPI) was developed and validated as a sensitive biomarker of disease progression. Longitudinal analysis demonstrated that Pompe-MDPI captured gait deterioration over one year, outperforming traditional measures like the six-minute walk test in sensitivity. These findings support the use of wearable gait analysis as a clinically meaningful, scalable tool for monitoring motor function in LOPD, with implications for both patient care and therapeutic trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12984-026-01898-8","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:22:24Z","timestamp":1773040944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Gait analysis reveals new outcome measures for monitoring disease progression in individuals with late-onset Pompe disease"],"prefix":"10.1186","volume":"23","author":[{"given":"Mireia","family":"Claramunt-Molet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Pegueroles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Pi-Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Rico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Idelsohn-Zielonka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Dom\u00ednguez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgilia","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Salabarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith K.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"D\u00edaz-Manera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"1898_CR1","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT van der Ploeg","year":"2008","unstructured":"van der Ploeg AT, Reuser AJ. Pompe\u2019s disease. Lancet. 2008;372:1342\u201353.","journal-title":"Lancet"},{"key":"1898_CR2","doi-asserted-by":"publisher","first-page":"e00446","DOI":"10.1016\/j.neurot.2024.e00446","volume":"21","author":"M Colpaert","year":"2024","unstructured":"Colpaert M, Singh PK, Donohue KJ, et al. Neurological glycogen storage diseases and emerging therapeutics. Neurotherapeutics. 2024;21:e00446.","journal-title":"Neurotherapeutics"},{"key":"1898_CR3","doi-asserted-by":"publisher","first-page":"e16383","DOI":"10.1111\/ene.16383","volume":"31","author":"B Schoser","year":"2024","unstructured":"Schoser B, van der Beek N, Broomfield A, et al. Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe consortium recommendation update 2024. Eur J Neurol. 2024;31:e16383.","journal-title":"Eur J Neurol"},{"key":"1898_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/ajmg.c.31322","volume":"160C","author":"A Schuller","year":"2012","unstructured":"Schuller A, Wenninger S, Strigl-Pill N, Schoser B. Toward deconstructing the phenotype of late-onset Pompe disease. Am J Med Genet C Semin Med Genet. 2012;160\u00a0C:80\u20138.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"1898_CR5","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.nmd.2019.06.011","volume":"29","author":"J Spiesshoefer","year":"2019","unstructured":"Spiesshoefer J, Henke C, Kabitz HJ, et al. The nature of respiratory muscle weakness in patients with late-onset Pompe disease. Neuromuscul Disord. 2019;29:618\u201327.","journal-title":"Neuromuscul Disord"},{"key":"1898_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ymgme.2015.09.001","volume":"116","author":"PT McIntosh","year":"2015","unstructured":"McIntosh PT, Case LE, Chan JM, Austin SL, Kishnani P. Characterization of gait in late onset Pompe disease. Mol Genet Metab. 2015;116:152\u20136.","journal-title":"Mol Genet Metab"},{"key":"1898_CR7","doi-asserted-by":"publisher","first-page":"102777","DOI":"10.1016\/j.humov.2021.102777","volume":"77","author":"C Starbuck","year":"2021","unstructured":"Starbuck C, Reay J, Silk E, Roberts M, Hendriksz C, Jones R. Are there common walking gait characteristics in patients diagnosed with late-onset Pompe disease? Hum Mov Sci. 2021;77:102777.","journal-title":"Hum Mov Sci"},{"key":"1898_CR8","doi-asserted-by":"crossref","unstructured":"Maulet T, Cattagni T, Mahmoudi S, et al. Characterization and related factors of postural control in adults with Late-Onset Pompe disease: Cross-Sectional and case control study. Phys Ther; 2025.","DOI":"10.1093\/ptj\/pzaf073"},{"key":"1898_CR9","doi-asserted-by":"publisher","first-page":"37040","DOI":"10.1038\/srep37040","volume":"6","author":"MS Valle","year":"2016","unstructured":"Valle MS, Casabona A, Fiumara A, Castiglione D, Sorge G, Cioni M. Quantitative analysis of upright standing in adults with late-onset Pompe disease. Sci Rep. 2016;6:37040.","journal-title":"Sci Rep"},{"key":"1898_CR10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3233\/JND-210663","volume":"8","author":"P De Blasiis","year":"2021","unstructured":"De Blasiis P, Fullin A, Sansone M, et al. Quantitative evaluation of upright posture by x-Ray and 3D stereophotogrammetry with a new marker set protocol in late onset Pompe disease. J Neuromuscul Dis. 2021;8:979\u201388.","journal-title":"J Neuromuscul Dis"},{"key":"1898_CR11","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1007\/s00415-021-10409-9","volume":"268","author":"K Gutschmidt","year":"2021","unstructured":"Gutschmidt K, Musumeci O, Diaz-Manera J, et al. STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase Alfa. J Neurol. 2021;268:2482\u201392.","journal-title":"J Neurol"},{"key":"1898_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nmd.2023.10.001","volume":"34","author":"RJ Martinez-Marin","year":"2024","unstructured":"Martinez-Marin RJ, Reyes-Leiva D, Nascimento A, et al. Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry. Neuromuscul Disord. 2024;34:1\u20138.","journal-title":"Neuromuscul Disord"},{"key":"1898_CR13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1186\/s13023-024-03373-w","volume":"19","author":"G Parenti","year":"2024","unstructured":"Parenti G, Fecarotta S, Alagia M, et al. The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid Maltase deficiency, glycogen storage disease type II). Orphanet J Rare Dis. 2024;19:408.","journal-title":"Orphanet J Rare Dis"},{"key":"1898_CR14","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/ene.13285","volume":"24","author":"AT van der Ploeg","year":"2017","unstructured":"van der Ploeg AT, Kruijshaar ME, Toscano A, et al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol. 2017;24:768\u2013e731.","journal-title":"Eur J Neurol"},{"key":"1898_CR15","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","volume":"20","author":"B Schoser","year":"2021","unstructured":"Schoser B, Roberts M, Byrne BJ, et al. Safety and efficacy of cipaglucosidase Alfa plus miglustat versus alglucosidase Alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurol. 2021;20:1027\u201337.","journal-title":"Lancet Neurol"},{"key":"1898_CR16","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","volume":"20","author":"J Diaz-Manera","year":"2021","unstructured":"Diaz-Manera J, Kishnani PS, Kushlaf H, et al. Safety and efficacy of avalglucosidase Alfa versus alglucosidase Alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol. 2021;20:1012\u201326.","journal-title":"Lancet Neurol"},{"key":"1898_CR17","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1093\/gerona\/glac085","volume":"77","author":"J Wang","year":"2022","unstructured":"Wang J, Wang J, Li X, et al. Association of pulmonary function with motor function trajectories and disability progression among older adults: A Long-Term Community-Based cohort study. J Gerontol Biol Sci Med Sci. 2022;77:2524\u201331.","journal-title":"J Gerontol Biol Sci Med Sci"},{"key":"1898_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13023-023-02974-1","volume":"19","author":"M Boentert","year":"2024","unstructured":"Boentert M, Berger KI, Diaz-Manera J, et al. Applying the win ratio method in clinical trials of orphan drugs: an analysis of data from the COMET trial of avalglucosidase Alfa in patients with late-onset Pompe disease. Orphanet J Rare Dis. 2024;19:14.","journal-title":"Orphanet J Rare Dis"},{"key":"1898_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","volume":"166","author":"Laboratories ATSCoPSfCPF","year":"2002","unstructured":"Laboratories ATSCoPSfCPF. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"1898_CR20","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/mus.27543","volume":"65","author":"C Tard","year":"2022","unstructured":"Tard C, Bayot M, Davion JB, et al. Factors impacting performance on the 6-minute walk test by people with late-onset Pompe disease. Muscle Nerve. 2022;65:693\u20137.","journal-title":"Muscle Nerve"},{"key":"1898_CR21","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/ene.15235","volume":"29","author":"S Bortolani","year":"2022","unstructured":"Bortolani S, Brusa C, Rolle E, et al. Technology outcome measures in neuromuscular disorders: A systematic review. Eur J Neurol. 2022;29:1266\u201378.","journal-title":"Eur J Neurol"},{"key":"1898_CR22","doi-asserted-by":"crossref","unstructured":"Migliorelli C, Gomez-Martinez M, Subias-Beltran P et al. Multidimensional Biomechanics-Based score to assess disease progression in Duchenne muscular dystrophy. Sens (Basel) 2023;23.","DOI":"10.3390\/s23020831"},{"key":"1898_CR23","doi-asserted-by":"publisher","first-page":"e16397","DOI":"10.1111\/ene.16397","volume":"31","author":"HA van Kooten","year":"2024","unstructured":"van Kooten HA, Horton MC, Wenninger S, et al. Improving outcome measures in late onset Pompe disease: modified Rasch-Built Pompe-Specific activity scale. Eur J Neurol. 2024;31:e16397.","journal-title":"Eur J Neurol"},{"key":"1898_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.gaitpost.2009.05.020","volume":"30","author":"R Baker","year":"2009","unstructured":"Baker R, McGinley JL, Schwartz MH, et al. The gait profile score and movement analysis profile. Gait Posture. 2009;30:265\u20139.","journal-title":"Gait Posture"},{"key":"1898_CR25","unstructured":"Lundberg S. A Unified Approach to Interpreting Model Predictions. Computer Science. 2017."},{"key":"1898_CR26","doi-asserted-by":"publisher","first-page":"e240045","DOI":"10.57264\/cer-2024-0045","volume":"13","author":"S Shohet","year":"2024","unstructured":"Shohet S, Hummel N, Fu S, et al. Comparing the efficacy of cipaglucosidase Alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data. J Comp Eff Res. 2024;13:e240045.","journal-title":"J Comp Eff Res"},{"key":"1898_CR27","doi-asserted-by":"publisher","first-page":"861136","DOI":"10.3389\/fnhum.2022.861136","volume":"16","author":"I Vandekerckhove","year":"2022","unstructured":"Vandekerckhove I, Van den Hauwe M, De Beukelaer N, et al. Longitudinal alterations in gait features in growing children with Duchenne muscular dystrophy. Front Hum Neurosci. 2022;16:861136.","journal-title":"Front Hum Neurosci"},{"key":"1898_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.gaitpost.2018.04.038","volume":"63","author":"M Goudriaan","year":"2018","unstructured":"Goudriaan M, Van den Hauwe M, Simon-Martinez C, et al. Gait deviations in Duchenne muscular dystrophy-Part 2. Statistical non-parametric mapping to analyze gait deviations in children with Duchenne muscular dystrophy. Gait Posture. 2018;63:159\u201364.","journal-title":"Gait Posture"},{"key":"1898_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/brain\/awh384","volume":"128","author":"ML Hagemans","year":"2005","unstructured":"Hagemans ML, Winkel LP, Van Doorn PA, et al. Clinical manifestation and natural course of late-onset pompe\u2019s disease in 54 Dutch patients. Brain. 2005;128:671\u20137.","journal-title":"Brain"},{"key":"1898_CR30","doi-asserted-by":"publisher","first-page":"e0163493","DOI":"10.1371\/journal.pone.0163493","volume":"11","author":"S Figueroa-Bonaparte","year":"2016","unstructured":"Figueroa-Bonaparte S, Segovia S, Llauger J, et al. Muscle MRI findings in Childhood\/Adult onset Pompe disease correlate with muscle function. PLoS ONE. 2016;11:e0163493.","journal-title":"PLoS ONE"},{"key":"1898_CR31","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/mus.27099","volume":"63","author":"J Diaz-Manera","year":"2021","unstructured":"Diaz-Manera J, Walter G, Straub V. Skeletal muscle magnetic resonance imaging in Pompe disease. Muscle Nerve. 2021;63:640\u201350.","journal-title":"Muscle Nerve"},{"key":"1898_CR32","doi-asserted-by":"publisher","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","volume":"93","author":"L Harlaar","year":"2019","unstructured":"Harlaar L, Hogrel JY, Perniconi B, et al. Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease. Neurology. 2019;93:e1756\u201367.","journal-title":"Neurology"},{"key":"1898_CR33","doi-asserted-by":"publisher","first-page":"9510","DOI":"10.1038\/s41598-019-45397-4","volume":"9","author":"F Moissenet","year":"2019","unstructured":"Moissenet F, Leboeuf F, Armand S. Lower limb sagittal gait kinematics can be predicted based on walking speed, gender, age and BMI. Sci Rep. 2019;9:9510.","journal-title":"Sci Rep"},{"key":"1898_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/1050-6411(91)90002-M","volume":"1","author":"L Arendt-Nielsen","year":"1991","unstructured":"Arendt-Nielsen L, Sinkjaer T, Nielsen J, Kallesoe K. Electromyographic patterns and knee joint kinematics during walking at various speeds. J Electromyogr Kinesiol. 1991;1:89\u201395.","journal-title":"J Electromyogr Kinesiol"},{"key":"1898_CR35","doi-asserted-by":"publisher","first-page":"e5517","DOI":"10.7717\/peerj.5517","volume":"6","author":"D Sun","year":"2018","unstructured":"Sun D, Fekete G, Mei Q, Gu Y. The effect of walking speed on the foot inter-segment kinematics, ground reaction forces and lower limb joint moments. PeerJ. 2018;6:e5517.","journal-title":"PeerJ"},{"key":"1898_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbiomech.2017.03.004","volume":"57","author":"YP Lim","year":"2017","unstructured":"Lim YP, Lin YC, Pandy MG. Effects of step length and step frequency on lower-limb muscle function in human gait. J Biomech. 2017;57:1\u20137.","journal-title":"J Biomech"}],"container-title":["Journal of NeuroEngineering and Rehabilitation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12984-026-01898-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12984-026-01898-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12984-026-01898-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T01:34:29Z","timestamp":1778031269000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12984-026-01898-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1898"],"URL":"https:\/\/doi.org\/10.1186\/s12984-026-01898-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7118240\/v1","asserted-by":"object"}]},"ISSN":["1743-0003"],"issn-type":[{"value":"1743-0003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Ethics Committee of the Hospital Nacional de Parapl\u00e9jicos in Toledo (Spain) and the University of Florida (USA). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M. Claramunt-Molet., J. Pegueroles, (A) Pi-Cervera., M. Rico, and S. Idelsohn-Zielonka are employees of Ephion Health, the company that developed the software and conducted the analyses for this study. Ephion Health holds a commercial interest in the software used. However, they had no role in the design of the study nor the clinical interpretation. C. Dom\u00ednguez-Gonz\u00e1lez, M. Corti, V. Ant\u00f3n, S. M. Salabarria, K. Wong, M. K. James, (B) J. Byrne and J. D\u00edaz-Manera declare no relevant disclosures. C. Dom\u00ednguez-Gonz\u00e1lez, M. Corti, V. Ant\u00f3n, S. M. Salabarria, K. Wong, M. K. James, B. J. Byrne and J. D\u00edaz-Manera declare no relevant disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}